Beyond lowering LDL cholesterol

被引:5
|
作者
Bayturan, Ozgur [1 ]
Utuk, Ozan [1 ]
Tuzcu, E. Murat [2 ]
机构
[1] Celal Bayar Univ, Tip Fak, Kardiyol Anabilim Dali, Manisa, Turkey
[2] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2011年 / 11卷 / 02期
关键词
Residual risk; LDL; atherogenic dyslipidemia; apolipoprotein B; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; VERY-LOW LEVELS; PHOSPHOLIPASE A(2); CARDIOVASCULAR EVENTS; HDL CHOLESTEROL; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; APOLIPOPROTEIN-B;
D O I
10.5152/akd.2011.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Compelling evidence from randomized controlled studies demonstrated the crucial role of lowering low-density lipoprotein cholesterol (LDL-C) in the prevention of vascular events. However, not all patients with low LDL-C levels show similar reduction in event rates. The residual risk factors associated with ongoing vascular events despite achieving low LDL-C levels remain to be elucidated. New data suggest that beyond statin therapy, inflammatory mediators, high non-HDL (high-density lipoprotein) cholesterol or apolipoprotein B, small dense LDL-C, type 2 diabetes mellitus, and lifestyle features may have impact on residual vascular risk. In this review, we discussed the significance of identifying these residual risk factors and developing new treatment strategies to further decrease vascular events. The importance of imaging arterial wall to evaluate the effect of various medical therapies has also stated. (Anadolu Kardiyol Derg 2011; 11: 163-7)
引用
收藏
页码:163 / 167
页数:5
相关论文
共 50 条
  • [1] Pharmacological strategies for lowering LDL cholesterol: statins and beyond
    Ariel Brautbar
    Christie M. Ballantyne
    Nature Reviews Cardiology, 2011, 8 : 253 - 265
  • [2] Pharmacological strategies for lowering LDL cholesterol: statins and beyond
    Brautbar, Ariel
    Ballantyne, Christie M.
    NATURE REVIEWS CARDIOLOGY, 2011, 8 (05) : 253 - 265
  • [3] The role of statins in clinical medicine - LDL - cholesterol lowering and beyond
    Rutishauser, J
    SWISS MEDICAL WEEKLY, 2006, 136 (3-4) : 41 - 49
  • [4] Lowering of LDL cholesterol
    Payne, N
    McCabe, C
    LANCET, 1999, 354 (9185): : 1207 - 1208
  • [5] Lowering of LDL cholesterol
    Sniderman, AD
    LANCET, 2000, 355 (9199): : 235 - 235
  • [6] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [7] Pleiotropic Effects of StatinsEvidence for Benefits Beyond LDL-Cholesterol Lowering
    Mario Marzilli
    American Journal of Cardiovascular Drugs, 2010, 10 : 3 - 9
  • [8] Pleiotropic Effects of StatinsEvidence Against Benefits Beyond LDL-Cholesterol Lowering
    Terje R. Pedersen
    American Journal of Cardiovascular Drugs, 2010, 10 : 10 - 17
  • [9] Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia
    Ibrahim, Shirin
    Reeskamp, Laurens F.
    de Goeij, Jim N.
    Hovingh, G. Kees
    Planken, R. Nils
    Bax, Willem A.
    Min, James K.
    Earls, James P.
    Knaapen, Paul
    Wiegman, Albert
    Stroes, Erik S. G.
    Nurmohamed, Nick S.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (07) : 892 - 900
  • [10] Pleiotropic Effects of Statins Evidence for Benefits Beyond LDL-Cholesterol Lowering
    Marzilli, Mario
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 : 3 - 9